Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + Restoret
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
aflibercept + Restoret is a combination therapy under clinical investigation for retinal diseases, specifically neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). Aflibercept is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor, preventing abnormal blood vessel growth in the retina. Restoret (EYE103), developed by EyeBiotech, is a tetravalent, tri-specific antibody functioning as an agonist of the Wingless-related integration site (Wnt) signaling pathway. The combination aims to address unmet needs in exudative retinal diseases by targeting both VEGF-mediated angiogenesis and activating Wnt signaling to promote vascular stability and repair. Early-phase clinical data indicate that this combination is well-tolerated with promising improvements in visual acuity and retinal thickness[1][5].
- Other names
- aflibercept + RestoretEYE103 + aflibercept
02
Targets
VEGFB (Vascular endothelial growth factor B)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)
Beyond the preview
Go deeper on aflibercept + Restoret.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + Restoret.